BioGaia

AGM Information • May 9, 2012

Press Release 9 May 2012

Annual General Meeting of BioGaia

The Annual General Meeting of BioGaia AB on 8 May 2012 voted to approve the following resolutions:

• a total dividend of SEK 6.00 per share
• re-election of Board members Jan Annwall, Stefan Elving, Thomas Flinck, David Dangoor, Inger Holmström, Jörgen Thorball and Paula Zeilon
• re-election of David Dangoor as Board Chairman
• payment of Board member compensation in an amount of SEK 300,000 to the Chairman and SEK 150,000 to each of the other Board members not employed by the company
• auditors' fee shall be paid according to approved account
• regarding principles for remuneration and other terms of employment for senior executives in accordance with the Board's proposal
• regarding the Nominating Committee in accordance with the Nominating Committee's proposal
• regarding the incentive scheme for the employees in accordance with the Board´s proposal
• regarding reduction of the statutory reserve in accordance with the Board´s proposal

All decisions that were passed by the Annual General Meeting are consistent with the Board's and Nominating Committee's previously published proposals.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00 Margareta Hagman, Executive Vice President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2012-05-08	BioGaia AB Interim report 1 January – 31 March 2012
2012-04-17	BioGaia signs exclusive distribution agreement for its probiotic drops and tablets in Taiwan
2012-04-04	Notice to attend the annual general meeting of BioGaia AB (publ)

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 9 May 2012, 08:00 am CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com